Aurobindo Pharma Sees Profit Growth Driven by Consistent Domestic Demand
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Source: Reuters
Profit Increase: Aurobindo Pharma reported a 3.8% rise in profit for the second quarter, reaching 8.48 billion rupees, driven by steady domestic demand for anti-retroviral drugs for HIV.
Revenue Growth: The company's revenue increased by 8.37% to 82.86 billion rupees, with 43.9% of its consolidated revenue coming from the U.S. market.
Market Challenges: Despite the profit and revenue growth, intense competition in the North American generics market continues to pressure margins for Aurobindo and its peers.
Policy Impact: U.S. tariffs on branded and patented drugs have not affected generic imports, providing some relief to the sector amidst ongoing competition.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
